This ADC product is comprised of an anti-SLC34A2 monoclonal antibody conjugated via a mc-VC-PABC linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- Similar to
- Lifastuzumab vedotin
(RG7599,DNIB0600A)
ADC Target
- Alternative Names
- SLC34A2; solute carrier family 34 (type II sodium/phosphate cotransporter), member 2; NPTIIb; NAPI-3B; NAPI-IIb; sodium-dependent phosphate transport protein 2B; sodium/phosphate cotransporter 2B; type II sodium-dependent phosphate transporter 3b; solute carrier family 34 (sodium phosphate), member 2;
- Target Entrez Gene ID
- 10568
- Overview
- The protein encoded by this gene is a pH-sensitive sodium-dependent phosphate transporter. Phosphate uptake is increased at lower pH. Defects in this gene are a cause of pulmonary alveolar microlithiasis. Three transcript variants encoding two different isoforms have been found for this gene.
ADC Antibody
- Overview
- Humanized Anti-SLC34A2 lgG1 Antibody, Lifastuzumab
- Generic name
- Lifastuzumab
ADC Linker
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
ADC payload drug
- Name
- MMAE (Monomethyl auristatin E)
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products